Targeting SLC1A5 in gastric cancer produces antitumor effects by inhibiting the mTOR/p-70S6K1 signaling pathway [63], glutamine mediates gastric cancer growth, and the efficacy of targeted glutamine therapy is dependent on the different expression patterns of the glutamine transporter ASCT2 and glutamate synthetase (GS) in specific gastric cancer groups [64], the new monoclonal antibody KM8094 has a very high therapeutic potential in targeting the neutral amino acid transporter ASCT2 [65, 66]. The gene discussed is MTOR; the disease is gastric cancer.